Shea Thomas A.

CIK 00016125502 companiesBOSTON, MA

SEC Profile

Transactions

Companies

Filings

CIK

0001612550

Recent Transactions

18 trades

Award
ALBIREO PHARMA, INC.
Stock Option (right to buy)
2018-06-08+30,000→ 30,000 total
Award
ALBIREO PHARMA, INC.
Stock Option (right to buy)
2017-08-21+13,000→ 13,000 total
Award
ALBIREO PHARMA, INC.
Stock Option (right to buy)
2017-01-20+20,000→ 20,000 total
Award
ALBIREO PHARMA, INC.
Stock Option (right to buy)
2016-11-03+62,947→ 62,947 total
Award
EPIRUS Biopharmaceuticals, Inc.
Restricted Stock Units
2016-05-27+230,000→ 230,000 total
Exercise/Conversion
EPIRUS Biopharmaceuticals, Inc.
Common Stock
2016-02-27+1,044→ 29,970 total
Exercise/Conversion
EPIRUS Biopharmaceuticals, Inc.
Common Stock
2016-02-27+3,073→ 33,043 total
Exercise/Conversion
EPIRUS Biopharmaceuticals, Inc.
Restricted Stock Units
2016-02-27−3,073→ 9,217 total
Exercise/Conversion
EPIRUS Biopharmaceuticals, Inc.
Restricted Stock Units
2016-02-27−1,044→ 0 total
Tax Payment
EPIRUS Biopharmaceuticals, Inc.
Common Stock
2016-02-27$2.80/sh−1,554→ 31,489 total
Exercise/Conversion
EPIRUS Biopharmaceuticals, Inc.
Employee Stock Option (Right to Buy)
2015-11-03−28,926→ 20,662 total
Exercise/Conversion
EPIRUS Biopharmaceuticals, Inc.
Common Stock
2015-11-03$1.30/sh+28,926→ 28,926 total
Award
EPIRUS Biopharmaceuticals, Inc.
Employee Stock Option (Right to Buy)
2015-11-02+56,842→ 56,842 total
Award
EPIRUS Biopharmaceuticals, Inc.
Employee Stock Option (Right to Buy)
2015-02-27+93,609→ 93,609 total
Award
EPIRUS Biopharmaceuticals, Inc.
Restricted Stock Units
2015-02-27+1,044→ 1,044 total
Award
EPIRUS Biopharmaceuticals, Inc.
Restricted Stock Units
2015-02-27+12,290→ 12,290 total
Award
EPIRUS Biopharmaceuticals, Inc.
Employee Stock Option (Right to Buy)
2014-07-15+49,588→ 49,588 total
Award
EPIRUS Biopharmaceuticals, Inc.
Employee Stock Option (Right to Buy)
2014-07-15+93,608→ 93,608 total

Companies

Recent Filings

Address

C/O EPIRUS BIOPHARMACEUTICALS, INC. 699 BOYLSTON STREET, 11TH FLOOR

BOSTON, MA, 02116

View on SEC.gov